BackIntellia Therapeutics Overview

Intellia Therapeutics Other Current Assets

Latest other current assets for NTLA: $83M.

Get informed when a big investor buys or sells

+ Follow
Other Current Assets
$82.75M
231.79% YoYΔ $57.81M vs prior year quarter

Peer average / median

Loading

Intellia Therapeutics Other Current Assets History

Loading

Intellia Therapeutics vs. peers: Other Current Assets Comparison

Loading

Intellia Therapeutics Other Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Intellia Therapeutics (NTLA) FAQ

Intellia Therapeutics (NTLA) currently reports a other current assets of $83M as of June 2026. That compares with $25M in the prior-year period — up 231.8% year over year. Use the charts on this page to explore Intellia Therapeutics's other current assets history and peer comparisons.

Intellia Therapeutics's other current assets increased from $25M to $83M — a 231.8% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Intellia Therapeutics reported $83M in other current assets as of June 2026. That compares with $25M in the prior-year period — up 231.8% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other current assets of $83M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Intellia Therapeutics, and consider following NTLA for alerts when major investors trade the stock.

Intellia Therapeutics is classified in the Healthcare sector. On other current assets, it currently shows $83M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing NTLA with unrelated industries.